title: [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
abstract: Prognosis and treatment of advanced melanoma have been transformed by the success of immunotherapies, in particular agents targeting PD-1. PD-L1 expression assessed by immunohistochemistry in not an effective predictive biomarker to select patients in this tumor type, since significant clinical benefit was observed in the group of patients with negative tumors. The predictive value of PD-L1 testing to select patients for combination of anti-PD-1 and anti-CTLA-4 agents is under evaluation. Other tissue biomarkers are emerging to identify sensitive tumors to anti-PD-1 agents. In particular, assessment of immune infiltrates in tumor tissue, mutational load and tumor neoantigens seem promising in melanoma.
authors.affiliation: Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif, France; Inserm U981, Gustave Roussy, 94805 Villejuif, France. Electronic address: julien.adam@gustaveroussy.fr.
authors.forename: Julien
authors.initials: J
authors.lastname: Adam
authors.affiliation: Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif, France.
authors.forename: Gorana
authors.initials: G
authors.lastname: Tomasic
authors.affiliation: Inserm U981, Gustave Roussy, 94805 Villejuif, France; Service de dermatologie, département de médecine, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif, France; Université Paris-Sud, faculté de médecine, 94270 Le Kremlin-Bicêtre, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Robert
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000037:antagonists & inhibitors / Q000276:immunology; D002986:Clinical Trials as Topic; D016903:Drug Monitoring; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008545:Melanoma / Q000737:chemistry / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D000077594:Nivolumab; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; D015415:Biomarkers; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab
keywords: Biomarkers; Biomarqueurs; Immunotherapies; Immunothérapie; Melanoma; Mélanome; PD-1; PD-L1